Seminars in Hematology
Volume 46 , Pages S5-S10 , April 2009

Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia

  • Carmen Fava
    • ,
  • Jorge Cortes

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jorge Cortes, MD, Professor of Medicine, Deputy Chair, Department of Leukemia, Chief, CML Section, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Editorial support was provided by Jeni Fagan (Health Interactions) on behalf of Novartis Oncology.

 STATEMENT OF CONFLICT OF INTEREST: Dr Cortes has received research grant support from Novartis Pharmaceuticals Corp; Dr. Fava has no relationships with the supplement sponsor to disclose.

PII: S0037-1963(09)00018-3

doi: 10.1053/j.seminhematol.2009.01.007

Seminars in Hematology
Volume 46 , Pages S5-S10 , April 2009

Article Tools

* Image Usage & Resolution